An established drug for recurrent multiple myeloma might effectively be repurposed to improve the survival and day-to-day lives of patients with devastating sickle cell disease, according to revealing new research by a Feinstein Institute for Medical Research scientist.
The study, by Lionel Blanc, PhD, an assistant investigator at the Feinstein Institute, will be published Dec. 17 in the journal Blood. Dr. Blanc’s research, performed in collaboration with the New York Blood Center, Yale School of Medicine and University of Montpellier in France, was the first to identify how the drug pomalidomide increases production of fetal hemoglobin, known to interfere with the so-called “sickling” of red blood cells implicated in sickle cell disease (SCD).
Illuminating pomalidomide’s mechanism of action offers proof of concept that the US Food and Drug Administration (FDA)-approved medication could potentially be used to treat SCD, representing better outcomes compared to current drug treatment for the 100,000 Americans with SCD, an inherited disorder causing poor oxygen delivery, organ damage and even death.
“We knew the drug would make fetal hemoglobin, but we didn’t know to what extent or how. That was the goal of the study,” explained Dr. Blanc, also an assistant professor of molecular medicine and pediatrics at Hofstra North Shore-LIJ School of Medicine and an Allied World St. Baldrick’s Scholar.
“We can also say something else – that hydroxyurea, the only FDA-approved drug for sickle cell anemia, was less effective than pomalidomide and appeared to act through a different mechanism of action,” he added. “The current therapy is good, but not everyone responds equally to hydroxyurea, and what we hope with pomalidomide is to improve this.”
Pomalidomide, a derivative of thalidomide used in advanced cases of the cancer multiple myeloma, works by killing malignant plasma cells. But Dr. Blanc and his colleagues demonstrated in the new research, performed on stem cells taken from five SCD patients and 120 normal controls, how pomalidomide also generated fetal hemoglobin, the fetal version of the protein in red blood cells that carries oxygen to body tissues.
In patients with congenital conditions producing anemia such as SCD and beta-thalassemia, fetal hemoglobin is normal, but adult hemoglobin – produced after birth – is abnormal. Therefore, reversing their production of adult hemoglobin back to fetal hemoglobin can reverse the course of their disease.
In addition to the 100,000 US residents with SCD, the condition also affects millions globally. “I would remind people that anemia impacts 1.6 billion people worldwide, making it a global economic burden,” Dr. Blanc notes.
Dr. Blanc and his colleagues in the Division of Hematology/Oncology at Cohen Children’s Medical Center of New York plan to launch a clinical trial in the near future in collaboration with other institutions to test pomalidomide, which is taken orally, in young adults with SCD.
Currently, the only potential cures for SCD are gene therapy, still in the experimental stage, or stem cell transplant, but these resource-intense treatments aren’t available to the vast majority of patients, particularly in the developing world.
“Our hope is to alleviate the symptoms of sickle cell disease by using a pill that could be made available to almost all patients, worldwide,” Dr. Blanc said.
Read more: Multiple Myeloma Drug Could Revolutionize Treatment for Sickle Cell Disease
The Latest on: Sickle Cell Disease
[google_news title=”” keyword=”Sickle Cell Disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Sickle Cell Disease
- Local doctor breaks down sickle cell disease in wake of Justin Johnson's deathon May 8, 2024 at 3:52 pm
Justin Johnson’s death has sparked a lot of online conversations about sickle cell disease. The Centers for Disease Control and Prevention reports approximately 100,000 Americans are affected by the ...
- May 18 brunch will offer sickle cell disease support in Albany areaon May 8, 2024 at 2:02 pm
The MTS Sickle Cell Foundation has partnered with the Georgia Public Library Service and the Dougherty County Library System to help raise awareness about sickle cell disease in the community. The ...
- Black 12-Year-Old Patient Begins New Sickle Cell Therapy Treatmenton May 7, 2024 at 8:39 am
A 12-year-old Black patient is the first to undergo a new gene therapy treatment for sickle cell disease, according to reports.
- A 12-Year-Old Is First to Start New Sickle Cell Treatmenton May 6, 2024 at 1:25 pm
He's the first patient outside of a clinical trial to start a new genetic treatment that was shown in clinical trials to cure 88% of people of the hallmark symptoms of sickle cell disease.
- Bluebird, Vertex prep for first commercial use of sickle cell gene therapieson May 6, 2024 at 9:33 am
A 12-year-old boy in the Washington, D.C., area is set become the first patient treated with Lyfgenia since its U.S. approval last December.
- First sickle cell patients begin gene therapy treatments by bluebird bio, Vertexon May 6, 2024 at 8:47 am
Five months after bluebird bio Inc. won FDA approval for its gene therapy to treat sickle cell disease, the Somerville company said its first patient has begun treatment.
- First Patient Begins Newly Approved Sickle Cell Gene Therapyon May 6, 2024 at 4:01 am
A 12-year-old boy in the Washington, D.C., area faces months of procedures to remedy his disease. “I want to be cured,” he said.
- ‘Life-changing’ drug for sickle cell disease to be offered by NHS in Englandon May 2, 2024 at 5:29 pm
Voxelotor, which can help reduce need for blood transfusions, is administered as a daily tablet ...
- A call for state funding for promising sickle cell disease treatmenton May 2, 2024 at 5:00 pm
Sickle cell disease is an incredibly painful genetic blood disorder. Those familiar with this disease know that it makes a normal life extremely difficult to manage. Although the Black community is ...
- 'Life-changing' sickle cell disease treatment made available on NHSon May 2, 2024 at 4:43 pm
A "life-changing" new treatment for people living with sickle cell disease is to be made available on the NHS. Around 4,000 people living with the potentially fatal blood disorder could see their ...
via Bing News